Abstract
BackgroundSeveral observational studies have shown that statin use may modify the risk of haematological malignancies. To quantify the association between statin use and risk for haematological malignancies, we performed a detailed meta-analysis of published studies regarding this subject.MethodsWe conducted a systematic search of multiple databases including PubMed, Embase, and Cochrane Library Central database up to July 2013. Fixed-effect and random-effect models were used to estimate summary relative risks (RR) and the corresponding 95% confidence intervals (CIs). Potential sources of heterogeneity were detected by meta-regression. Subgroup analyses and sensitivity analysis were also performed.ResultsA total of 20 eligible studies (ten case-control studies, four cohort studies, and six RCTs) reporting 1,139,584 subjects and 15,297 haematological malignancies cases were included. Meta-analysis showed that statin use was associated with a statistically significant 19% reduction in haematological malignancies incidence (RR = 0.81, 95% CI [0.70, 0.92]). During subgroup analyses, statin use was associated with a significantly reduced risk of haematological malignancies among observational studies (RR = 0.79, 95% CI [0.67, 0.93]), but not among RCTs (RR = 0.92, 95% CI [0.77, 1.09]).ConclusionsBased on this comprehensive meta-analysis, statin use may have chemopreventive effects against haematological malignancies. More studies, especially definitive, randomized chemoprevention trials are needed to confirm this association.
Highlights
Hematologic malignancies, including three major groups: leukemia, lymphoma, and plasma cell neoplasms, derive from cells of the bone marrow and the lymphatic system [1]
To better understand this issue, we carried out a meta-analysis of existing RCTs and observational studies that investigated the association between statin use and the risk of developing haematological malignancies
Studies considered in this metaanalysis were either RCTs or observational studies that met the following inclusion criteria: (i) evaluated and clearly defined exposure to statins, (ii) reported haematological malignancies incidence and (iii) presented odds ratio (OR), relative risk (RR), or hazard ratio (HR) estimates with its 95% confidence interval (CI), or provided data for their calculation
Summary
Hematologic malignancies, including three major groups: leukemia, lymphoma, and plasma cell neoplasms, derive from cells of the bone marrow and the lymphatic system [1]. Several randomized controlled trials(RCTs) and epidemiologic studies have evaluated the association between statin use and the risk of haematological malignancies; the existing results are inconsistent. To better understand this issue, we carried out a meta-analysis of existing RCTs and observational studies that investigated the association between statin use and the risk of developing haematological malignancies. Several observational studies have shown that statin use may modify the risk of haematological malignancies. To quantify the association between statin use and risk for haematological malignancies, we performed a detailed metaanalysis of published studies regarding this subject
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
